CDC Website CDC Website

To Join the NPIN community or

Home » Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals (R21 Clinical Trial Not Allowed)

Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or following vaccination with Bacillus Calmette-Gurin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected or uninfected individuals. Development of novel functional assays to assess host response and inclusion of immune profiling and systems biology approaches are encouraged. This FOA seeks to stimulate innovative research in deciphering immune mechanisms in humans required for protection from Mtb infection or tuberculosis (TB) disease, or induced by TB vaccines that go beyond what have traditionally been investigated in TB.

Application Due Date
1/14/19
Award Date
7/1/19
Application Contact
Ann
Devine
Branch Chief, Grants Management Officer/AIDS and CTU Division Coordinator
240-669-2966
adevine@niaid.nih.gov
Technical Contact
Cesar
Boggiano, PhD
Health Specialist
cesar.boggiano@nih.gov
240-627-3038
Fund Duration
The total project period may not exceed 2 years.
Subjects
Audiences
Focus Area

Fund Number: 

5422

Fund ID: 

PAR-18-923

Last Updated: 

9/21/18